艾替班特与C1酯酶/激肽释放酶抑制剂治疗重症COVID-19的疗效与安全性评价:三臂随机对照试验研究方案
研究假设缓激肽在肺部蓄积是驱动COVID-19肺炎和呼吸衰竭的重要机制,抑制缓激肽可能减轻肺部炎症反应,改善疾病严重程度和死亡率。
要点
- 重症COVID-19中缓激肽蓄积可能驱动肺炎和呼吸衰竭。
- 试验比较C1酯酶/激肽释放酶抑制剂、艾替班特与标准治疗。
- 主要目标为评估抑制缓激肽对疾病严重程度和死亡率的影响。
核心结论
- 抑制缓激肽可能减轻重症COVID-19患者的肺部炎症反应,对疾病严重程度和死亡率产生积极影响。
主要发现
- 动物模型中ACE2失活导致脂多糖诱导的严重急性肺炎,抑制缓激肽几乎完全恢复肺结构。
- ACE抑制剂导致缓激肽在肺部蓄积是咳嗽的常见副作用。
关键数值与推荐
- C1酯酶/激肽释放酶抑制剂组:第1天和第4天静脉给予20 U/kg,加标准治疗。
- 艾替班特组:皮下注射30 mg,每日三次,持续4天,加标准治疗。
- 标准治疗组:根据已发表临床试验推荐,包括补氧、无创和有创通气、抗生素、抗炎药、预防性抗血栓治疗、升压支持和肾脏替代治疗。
临床怎么用
- 针对缓激肽通路的抑制可能成为重症COVID-19的治疗策略,需等待试验结果验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: SARS-CoV-2, the virus that causes COVID-19, enters the cells through a mechanism dependent on its binding to angiotensin-converting enzyme 2 (ACE2), a protein highly expressed in the lungs. The putative viral-induced inhibition of ACE2 could result in the defective degradation of bradykinin, a potent inflammatory substance. We hypothesize that increased bradykinin in the lungs is an important mechanism driving the development of pneumonia and respiratory failure in COVID-19. METHODS: This is a phase II, single-center, three-armed parallel-group, open-label, active control superiority randomized clinical trial. One hundred eighty eligible patients will be randomly assigned in a 1:1:1 ratio to receive either the inhibitor of C1e/kallikrein 20 U/kg intravenously on day 1 and day 4 plus standard care; or icatibant 30 mg subcutaneously, three doses/day for 4 days plus standard care; or standard care alone, as recommended in the clinical trials published to date, which includes supplemental oxygen, non-invasive and invasive ventilation, antibiotic agents, anti-inflammatory agents, prophylactic antithrombotic therapy, vasopressor support, and renal replacement therapy. DISCUSSION: Accumulation of bradykinin in the lungs is a common side effect of ACE inhibitors leading to cough. In animal models, the inactivation of ACE2 leads to severe acute pneumonitis in response to lipopolysaccharide (LPS), and the inhibition of bradykinin almost completely restores the lung structure. We believe that inhibition of bradykinin in severe COVID-19 patients could reduce the lung inflammatory response, impacting positively on the severity of disease and mortality rates. TRIAL REGISTRATION: Brazilian Clinical Trials Registry Universal Trial Number (UTN) U1111-1250-1843. Registered on May/5/2020.
引用
- Mansour E, Bueno FF, de Lima-Júnior JC, et al. Evaluation of the efficacy and safety of icatibant and C1 esterase/kallikrein inhibitor in severe COVID-19: study protocol for a three-armed randomized controlled trial. Trials. 2021. PMID: 33472675. doi:10.1186/s13063-021-05027-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。